In particular, patients with advanced fibrosis (F3) or cirrhosis (F4), have a substantial residual risk of HCC that remains after viral eradication.

Sep 23, 2024 · Achieving a sustained virologic response (SVR) through direct-acting antivirals for hepatitis C virus (HCV) infection significantly reduces the long-term risk of hepatocellular …

Promising strategies for estimating HCC risk include simplified scoring systems (such as fibrosis-4), liver elastography and multivariable HCC risk calculators. Such tools may enable risk …

Eradication of HCV by antiviral treatment reduces but does not eliminate the risk of hepatocellular carcinoma (HCC). In particular, patients with advanced brosis (F3) or cirrhosis (F4), have a. …

However, individual patients carry a variety of risk factors that modify their HCC risk after SVR, including most importantly fibrosis stage (F3 versus F4) but also age, sex, albumin level, …

Feb 24, 2022 · The HCC risk model. GAF criteria based on gamma‐glutamyl transpeptidase, AFP, and FIB‐4 index at any point after SVR can help identify patients at negligible risk of …

Patients with baseline F3‐4 fibrosis treated with new oral direct‐acting antivirals who had reached a SVR were regularly followed as part of the HCC surveillance strategy. Six models were …

HCV eradication by antiviral treatment reduces but does not eliminate HCC risk. Patients with established cirrhosis require HCC surveillance "indefinitely" after sustained virologic response …

Dec 20, 2018 · We designed a Markov cohort, state-transition model to evaluate the cost effectiveness of biannual and annual surveillance for HCC in 50-year-old patients with …

Oct 10, 2017 · HCC typically develops in F4 disease; low SVR rates were seen in HCC patients in this population. These results support HCV treatment prior to progression to F4 to allow for …